{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T07:05:01Z","timestamp":1772348701571,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bulcan.2024.01.014","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T12:28:15Z","timestamp":1741696095000},"page":"619-625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recommandations fran\u00e7aises de prise en charge des tumeurs d\u2019Ewing m\u00e9tastatiques extra-pulmonaires (GroupOs)"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-3986","authenticated-orcid":false,"given":"Sarah","family":"Winter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thibaud","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Ducassou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Helfre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Berlanga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauriane","family":"Lemelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Marie-Cardine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascaline Boudou","family":"Rouquette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Laurence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 4","key":"10.1016\/j.bulcan.2024.01.014_bib0110","doi-asserted-by":"crossref","first-page":"iv79","DOI":"10.1093\/annonc\/mdy310","article-title":"Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2024.01.014_bib0115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2022.11.002","article-title":"Staging of newly diagnosed Ewing sarcoma: results of bone marrow aspiration and biopsy versus 18(FDG)-PET\/CT imaging for bone marrow involvement","volume":"179","author":"Guinot","year":"2022","journal-title":"EJC"},{"issue":"8","key":"10.1016\/j.bulcan.2024.01.014_bib0120","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1097\/CORR.0000000000001681","article-title":"What is the comparative ability of 18F-FDG PET\/CT, 99mTc-MDP skeletal scintigraphy, and whole-body MRI as a staging investigation to detect skeletal metastases in patients with osteosarcoma and Ewing sarcoma?","volume":"479","author":"Aryal","year":"2021","journal-title":"Clin Orthop"},{"issue":"Suppl. 15","key":"10.1016\/j.bulcan.2024.01.014_bib0125","doi-asserted-by":"crossref","first-page":"11500","DOI":"10.1200\/JCO.2020.38.15_suppl.11500","article-title":"Comparison of two chemotherapy regimens in Ewing sarcoma (ES): Overall and subgroup results of the Euro Ewing 2012\u00a0randomized trial (EE2012)","volume":"38","author":"Brennan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.bulcan.2024.01.014_bib0130","article-title":"Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES)","volume":"40","author":"McCabe","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2024.01.014_bib0135","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/pbc.20719","article-title":"Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors","volume":"47","author":"Hunold","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"15","key":"10.1016\/j.bulcan.2024.01.014_bib0140","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1200\/JCO.2001.19.15.3463","article-title":"Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study","volume":"19","author":"Saylors","year":"2001","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2024.01.014_bib0145","doi-asserted-by":"crossref","first-page":"e28844","DOI":"10.1002\/pbc.28844","article-title":"Prognostic and therapeutic factors influencing the clinical outcome of metastatic Ewing sarcoma family of tumors: a retrospective report from the Japan Ewing Sarcoma Study Group","volume":"68","author":"Umeda","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"20","key":"10.1016\/j.bulcan.2024.01.014_bib0150","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2009.22.9864","article-title":"Primary disseminated Multifocal Ewing sarcoma: results of the Euro-EWING 99\u00a0Trial","volume":"28","author":"Ladenstein","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2024.01.014_bib0155","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/COC.0b013e3182467ede","article-title":"Radiotherapy in metastatic Ewing sarcoma","volume":"36","author":"Paulino","year":"2013","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2024.01.014_bib0160","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/cncr.24740","article-title":"The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES)","volume":"116","author":"Haeusler","year":"2010","journal-title":"Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.bulcan.2024.01.014_bib0165","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00066-009-1009-9","article-title":"Radiation toxicity following busulfan\/melphalan high-dose chemotherapy in the EURO-EWING-99-trial: review of GPOH data","volume":"185","author":"B\u00f6lling","year":"2009","journal-title":"Strahlenther Onkol Organ Dtsch Rontgengesellschaft Al"},{"issue":"5","key":"10.1016\/j.bulcan.2024.01.014_bib0170","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.clon.2005.03.004","article-title":"Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice","volume":"17","author":"Seddon","year":"2005","journal-title":"Clin Oncol R Coll Radiol"},{"issue":"3","key":"10.1016\/j.bulcan.2024.01.014_bib0175","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/pbc.25294","article-title":"Radiation for bone metastases in Ewing sarcoma and rhabdomyosarcoma","volume":"62","author":"Casey","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bulcan.2024.01.014_bib0180","doi-asserted-by":"crossref","first-page":"418270","DOI":"10.1155\/2014\/418270","article-title":"Stereotactic body radiotherapy for metastatic and recurrent ewing sarcoma and osteosarcoma","volume":"2014","author":"Brown","year":"2014","journal-title":"Sarcoma"},{"issue":"2","key":"10.1016\/j.bulcan.2024.01.014_bib0185","doi-asserted-by":"crossref","first-page":"951","DOI":"10.21873\/anticanres.14028","article-title":"Aggressive local control with multisite stereotactic body radiation in metastatic Ewing sarcoma: a literature review and case report","volume":"40","author":"Karimi","year":"2020","journal-title":"Anticancer Res"},{"issue":"7)","key":"10.1016\/j.bulcan.2024.01.014_bib0190","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/cncr.20544","article-title":"Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European rhabdomyosarcoma protocol","volume":"101","author":"Casanova","year":"2004","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.bulcan.2024.01.014_bib0195","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/S0149-2918(08)80059-8","article-title":"Metronomic etoposide\/cyclophosphamide\/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study","volume":"30","author":"Andre","year":"2008","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.bulcan.2024.01.014_bib0200","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1158\/1078-0432.CCR-05-1541","article-title":"Phase I evaluation of oral and intravenous vinorelbine in pediatric cancer patients: a report from the Children's Oncology Group","volume":"12","author":"Johansen","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.bulcan.2024.01.014_bib0205","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1023\/A:1013180903805","article-title":"Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors","volume":"12","author":"Marty","year":"2001","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2024.01.014_bib0105","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00280-007-0510-z","article-title":"Evaluation of oral versus intravenous dose of vinorelbine to achieve equivalent blood exposures in patients with solid tumours","volume":"60","author":"Bourgeois","year":"2007","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125000815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125000815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T20:01:26Z","timestamp":1749240086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125000815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0007455125000815"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.01.014","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommandations fran\u00e7aises de prise en charge des tumeurs d\u2019Ewing m\u00e9tastatiques extra-pulmonaires (GroupOs)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer.","name":"copyright","label":"Copyright"}]}}